The Anchor Drug in Rheumatology: Join Discussion Live: 20th Sept 12.00 - 13.00 BST
Rheumatoid arthritis is an autoinflammatory condition affecting 1% of the adult population, often hallmarked by chronic synovitis. Left untreated it leads to joint pain, swelling and disability. Up to 70% of patients become work-disabled within 5-10 years of symptom onset.
Effective in 50% of early Rheumatoid Arthritis, Methotrexate is one of the first-line disease modifying anti-rheumatic drugs (DMARDs) licensed for treatment. Also used in the treatment of Psoriasis, this revolutionary drug has proven its impact in combination with more advanced therapies such as TNF inhibitors. Response is not, however, universal.
Learning Goals:
How to improve adherence to methotrexate therapy
Which patients experience side effects to methotrexate
What is the impact of immunogenicity on TNF-inhibitor response and how does methotrexate enhance TNF-inhibitor response
What questions will be raised in thiswebinar?
What are the barriers to methotrexate adherence?
What are the main side effects patients experience in an observational cohort study?
How does methotrexate affect TNF-inhibitor response?
JOIN THE DISCUSSION LIVE
20th September 2024
12:00-13:00 BST
For more information about our webinars and events, please visit www.aopgbi.org
